Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Depreciation & Amortization - Total (2016 - 2019)

Amicus Therapeutics (FOLD) has disclosed Depreciation & Amortization - Total for 6 consecutive years, with $991000.0 as the latest value for Q1 2019.

  • For the quarter ending Q1 2019, Depreciation & Amortization - Total rose 2.27% year-over-year to $991000.0, compared with a TTM value of $991000.0 through Dec 2019, down 76.4%, and an annual FY2025 reading of $3.9 million, down 22.0% over the prior year.
  • Depreciation & Amortization - Total was $991000.0 for Q1 2019 at Amicus Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Depreciation & Amortization - Total topped out at $1.2 million in Q4 2018 and bottomed at $353000.0 in Q2 2015.
  • Average Depreciation & Amortization - Total over 5 years is $834333.3, with a median of $896000.0 recorded in 2016.
  • The sharpest move saw Depreciation & Amortization - Total decreased 10.86% in 2015, then surged 126.84% in 2016.
  • Year by year, Depreciation & Amortization - Total stood at $395000.0 in 2015, then skyrocketed by 129.37% to $906000.0 in 2016, then rose by 22.19% to $1.1 million in 2017, then grew by 7.05% to $1.2 million in 2018, then dropped by 16.37% to $991000.0 in 2019.
  • Business Quant data shows Depreciation & Amortization - Total for FOLD at $991000.0 in Q1 2019, $1.2 million in Q4 2018, and $1.1 million in Q3 2018.